Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 34Lymphoma, Non-Hodgkin 25Lymphoma, Follicular 25Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 16Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large-Cell, Immunoblastic 8Waldenstrom Macroglobulinemia 6Lymphoma, B-Cell 5Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia 2Orbital lymphoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × ibritumomab tiuxetan × Clear all
NCT00477815 2018-05-14

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Mayo Clinic

Phase 1 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡